达格列净治疗2型糖尿病并冠心病患者的临床效果及对患者凝血功能的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (580 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy of Dapagliflozin for patients with type 2 diabetes and coronary heart disease (T2DM/CHD) and its effect on the coagulation function of the patients. Methods A total of 86 T2DM/CHD patients admitted to Anshan Central Hospital from June 2019 to March 2021 were selected as the subjects, and they were divided into control group and observation group according to random number table method, with 43 cases in each group. The control group was given Metformin Hydrochloride, and the observation group was given Dapagliflozin on the basis of the control group. Both groups were treated for 3 consecutive months. The fasting blood glucose (FPG),glycosylated hemoglobin (HbA1c), triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), thrombin time (TT), activated partial thromboplastin time(APTT), D-dimer (D-D), fibrinogen (FIB) were compare between the two groups. Results There were no significant differences in FPG, HbA1c, TG, TC, HDL-C, LDL-C, TT, APTT, D-D and FIB between the two groups before treatment(P＞0.05). After treatment, FPG, HbA1c, FINS, TG, TC, LDL-C, D-D and FIB in the two groups were lower than those before treatment, the differences were statistically significant (P＜0.05). After treatment, HDL-C levels in the two groups were higher than those before treatment, the differences were statistically significant (P＜0.05). After treatment, TT and APTT in the two groups were longer than those before treatment, the differences were statistically significant (P＜0.05).After treatment, FPG, HbA1c, FINS, TG, TC, LDL-C, D-D and FIB in observation group were lower than those in control group, the differences were statistically significant (P＜0.05). After treatment, the HDL-C of observation group was higher than that of control group, the difference was statistically significant (P＜0.05). After treatment, TT and APTT of observation group were longer than those in the control group, the differences were statistically significant (P＜0.05).Conclusions Dapagliflozin is effective in treating patients with the T2DM/CHD, and has obvious advantages in improving blood glucose, blood lipids, and the body's hypercoagulable state.

Key words： Type 2 diabetes Coronary heart disease Dapagliflozin Clinical efficacy Coagulation function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIN Li

Cite this article:

XIN Li. Clinical efficacy of Dapagliflozin for patients with type 2 diabetes and coronary heart disease and its effect on the coagulation function of the patients[J]. 中国当代医药, 2022, 29(4): 93-96.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I4/93

[1]	赵大可，胡大勇.糖尿病大血管病变多组学研究进展[J].医学综述，2021，27（1）：146-152.
[2]	Artime E，Romera I，Díaz-Cerezo S，et al.Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain：A Systematic Review[J].Diabetes Ther，2021，12（6）：1631-1659.
[3]	王亚东，杨延泽，魏金娜，等.SGLT2 抑制剂对糖尿病大血管并发症及心衰的治疗研究进展[J].江苏大学学报（医学版），2021，31（3）：1-7.
[4]	陈姣，周杰，汤冰倩，等.达格列净治疗糖尿病合并心衰的疗效及其血管内皮功能和炎症因子的影响[J].心血管康复医学杂志，2020，31（5）：599-603.
[5]	叶任高，陆再英.内科学[M].北京：人民卫生出版社，2000：798-802.
[6]	中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2013年版）[J].中国糖尿病杂志，2014，22（8）：2-42.
[7]	魏碧玥，梁梅花.糖尿病引起动脉粥样硬化作用机制研究的进展[J].心血管康复医学杂志，2021，30（1）：85-87.
[8]	Dharmalingam M，Aravind SR，Thacker H，et al.Efficacy and Safety of Remogliflozin Etabonate，a New Sodium Glucose Co-Transporter-2 Inhibitor，in Patients with Type 2 Diabetes Mellitus：A 24-Week，Randomized，Double-Blind，Active-Controlled Trial[J].Drugs，2020，80（6）：587-600.
[9]	Liu Z，Ma X，Ilyas I，et al.Impact of sodium glucose cotransporter 2（SGLT2）inhibitors on atherosclerosis：from pharmacology to pre-clinical and clinical therapeutics[J].Theranostics，2021，11（9）：4502-4515.
[10]	邓宁，胡庆芬，梁彩虹，等.达格列净片联合盐酸二甲双胍对2 型糖尿病患者的临床研究[J].中国临床药理学杂志，2019，35（18）：2016-2018.
[11]	杨洋，魏鹏翔，张村，等.达格列净联合常规降糖药治疗糖尿病有效性和安全性的Meta 分析[J].中国循证医学杂志，2019，19（12）：1436-1445.
[12]	陈春燕，张时清，张浩，等.达格列净联合二甲双胍对糖尿病患者的临床疗效及相关内分泌激素水平的影响[J].中国临床医生杂志，2020，48（9）：1045-1047.
[13]	杨艳玲，汤云昭，倪长霖.达格列净联合二甲双胍与吡格列酮治疗2 型糖尿病的临床观察[J].中国慢性病预防与控制，2019，27（8）：611-613.
[14]	陈海波，金鑫，叶靖，等.高凝状态与糖尿病血管相关并发症的关系[J].血栓与止血学，2017，23（4）：633-635.
[15]	罗璇.联合应用地特胰岛素及瑞格列奈治疗2 型糖尿病的效果[J].中国现代医生，2021，59（17）：38-40.
[16]	林树发，刘贞仔，刘天宝.门冬胰岛素30 注射液治疗2型糖尿病患者的效果[J].中国现代医生，2021，59（26）：55-58.
[17]	郝雁红，吴清，李云，等.达格列净联合缬沙坦胶囊在2型糖尿病合并新发高血压患者中的应用效果[J].中国当代医药，2021，28（17）：67-70.
[18]	朱长东，曾小兵，谢宝强，等.阿格列汀治疗2 型糖尿病合并冠心病的临床效果[J].中国当代医药，2020，27（11）：63-66.
[19]	武洋，李贝贝，孙明明，等.冠心病合并2 型糖尿病患者的抗血小板治疗病例分析[J].中国医药科学，2020，10（12）：254-256.
[20]	盘德辉，李翠君，姚剑坤，等.血糖控制水平对2 型糖尿病合并冠心病病人血液高凝状态及血栓栓塞事件的影响[J].中西医结合心脑血管病杂志，2020，18（13）：2097-2100.
[21]	张耀颐，田晨光.达格列净对2 型糖尿病合并颈动脉粥样硬化患者机体中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、C 反应蛋白、白介素6 的影响[J].中国当代医药，2021，28（13）：119-122.